Articles published by Evaxion Biotech
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
February 29, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
February 20, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 07, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Announces Closing of $15 Million Public Offering
February 06, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Biotech Announces Pricing of $15 Million Public Offering
February 01, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
January 24, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Announces Completion of ADS Ratio Change
January 22, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Announces Plan to Implement ADS Ratio Change
January 08, 2024
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Biotech Announces Closing of Private Placement
December 21, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Biotech Announces Private Placement Financing
December 19, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
November 28, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
November 15, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
November 06, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01
October 31, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/5dde143b-e9d0-4c17-a4e1-eb65dadb8a7c/small/image1-1-png.png)
New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
October 26, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/119c55f9-f3a6-4d62-bca9-0ee4d0daf174/small/evaxion-logo-png.png)
![](https://ml-eu.globenewswire.com/media/119c55f9-f3a6-4d62-bca9-0ee4d0daf174/small/evaxion-logo-png.png)
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
September 20, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/119c55f9-f3a6-4d62-bca9-0ee4d0daf174/small/evaxion-logo-png.png)
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
September 18, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/119c55f9-f3a6-4d62-bca9-0ee4d0daf174/small/evaxion-logo-png.png)
![](https://ml-eu.globenewswire.com/media/119c55f9-f3a6-4d62-bca9-0ee4d0daf174/small/evaxion-logo-png.png)
![](https://ml-eu.globenewswire.com/media/119c55f9-f3a6-4d62-bca9-0ee4d0daf174/small/evaxion-logo-png.png)
![](https://ml-eu.globenewswire.com/media/119c55f9-f3a6-4d62-bca9-0ee4d0daf174/small/evaxion-logo-png.png)
Evaxion announces financing commitments totaling up to USD 20 million with Negma Group
August 01, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
![](https://ml-eu.globenewswire.com/media/119c55f9-f3a6-4d62-bca9-0ee4d0daf174/small/evaxion-logo-png.png)
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
July 31, 2023
From Evaxion Biotech
Via GlobeNewswire
Tickers
EVAX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.